Why, roughly $200MM is cash, revenues from Roche T-DM1 of approx 5% of Billions (eventually hundreds of millions per year at peak) in free cash flow, pipeline, partners, patents, technology platform, plenty of costs available to cut at IMGN. IMGN shareholders respect SGEN management more than IMGN management and would take SGEN stock in the $18-20 range if done soon. SGEN should make a move now IMO.